Business
Drug Shortages Are Costly to Patients and to Payers
The Hidden Market of Counterfeit Drugs a Concern for All Stakeholders
The Clinical Toll of Nonvalvular Atrial Fibrillation Poses Significant Economic Burden
Michael S. Broder, MD, MSHS, Claudio Faria, PharmD, MPH, Annette Powers, PharmD, MBA, Jehangeer Sunderji, MD, Dasha Cherepanov, PhD
The Value of Pharmaceuticals in the Prevention and Treatment of CINV
Disruptive Innovation, Uncertain Value, and Economic Modeling in Oncology
Christopher M. Blanchette, PhD, MBA, Nicholas J. Gross, MD, PhD, Pablo Altman, MD, MBA, F. Randy Vogenberg, PhD
Chronic Obstructive Pulmonary Disease Remains a Growing Population Health Concern
Schizophrenia: “The Forgotten Illness”?
Breakthrough Therapy, or Breakthrough Pricing?
Andrew Paris, MBA, Chris M. Kozma, PhD, Wing Chow, PharmD, MPH, Anisha M. Patel, MS, Samir H. Mody, PharmD, MBA, Myoung S. Kim, PhD, MBA
Can Substituting Generic Drugs with Brand-Name Agents for Acute Pain Postsurgery Help to Deliver Cost-Effective, Quality Care?
Modeling the Future Economic Impact of Biosimilars’ Entry into the US Market
